Business Wire

NY-HANSHOW

16.1.2023 15:01:38 CET | Business Wire | Press release

Share
Hanshow Unveils New Generation Protocol and Four-Color ESL at NRF 2023

Hanshow participated in the 2023 National Retail Federation (NRF), the largest retail event in the world. At this year’s NRF Exhibition Booth, Hanshow unveiled a new generation protocol high-density low-power cellular network (HiLPC) and four-color Electronic Shelf Label (ESL). Hanshow has strengthened the operability of both its hardware and software and now provides more advanced solutions and services for the digital upgrading of retail industry customers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230111005732/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Hanshow's new generation protocol high-density low-power cellular network (HiLPC) (Graphic: Business Wire)

Rapid upgrading that is more than just “fast”

Hanshow already provided the world’s leading series of ESL products, and this advanced performance has been further improved through Hanshow’s new generation HiLPC. With HiLPC innovative system architecture, the communication speed of the ESL is greatly improved, and the update speed can reach over 60,000 pieces/hour/ESL controller, making it quicker and easier to install and bind. The super-high system throughput of the HiLPC enables updating tens of millions of devices within a few minutes, which brings clients a totally novel experience of real-time ESL services and enhances clients’ capability of managing globally distributed stores.

With this upgraded protocol, Hanshow ESL Solution enables batch, timed, and synchronized task updates in the same store with errors controlled at the millisecond level, and it can also synchronize dynamic price changes, realize precise timing synchronization while online and even offline, and track the position of products, greatly improving the operational efficiency of stores.

The new generation HiLPC makes it possible to nomadically update ESLs, which opens opportunities for new industrial applications. It also supports flashing light prompts for any number of goods being selected to help employees quickly find the location of goods for sorting. It supports dynamic network resource allocation used in conjunction with Wi-Fi, solving the network incompatibility challenges. In addition, the new generation protocol combined with ESL controllers and financial-grade security chips provides the most reliable data protection available.

Breaking through with smarter and better performance

Hanshow also unveiled the four-color ESL product series that supports black, white, red, and yellow color displays in any combination, expanding the digital display possibilities for retailers. This product’s screen updating and flashing speeds are significantly optimized compared with previous models, especially in conjunction with the new generation HiLPC.

In addition to the breakthrough in vivid displays, Hanshow has focused on increasing its precision applications for specific industry demands. Hanshow’s thermal detector and DIY ESL solutions are designed to help retailers solve special applications for temperature monitoring and automatic temperature change alerts, as well as the product use adaptation problems of home improvement retail and other business forms.

For years, Hanshow has pursued continuous innovation based on customer needs and remained committed to enabling customers to achieve upgrading for better operational efficiency. The new generation HiLPC and four-color ESL directly achieve this by drastically reducing the energy supply and paper materials needed to operate a physical store. In the future, Hanshow will continue developing innovative digital technology, fully assist customers in digital upgrading, and create a green, leading, and sustainable digital new experience in the industry.

About Hanshow

Hanshow is a global leader in developing and manufacturing electronic shelf labels and digital store solutions, offering global customers a series of world-class customized IoT touchpoints and digital store solutions that deliver customer-centric insights. Hanshow’s solutions are used by over 30,000 stores in more than 50 countries, helping retailers streamline operations, optimize pricing strategies, and offer consumers a more personalized experience. Learn more: www.hanshow.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230111005732/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye